Study patients had high-grade serous, platinum-resistant ovarian cancer and a median of four prior lines of therapy. Call ...
Among 459 participants, more with blood in urine saw it resolve on sefaxersen than placebo; blinded follow-up will measure ...
Share-transfer books are expected to close Nov. 5. Elme plans to move remaining assets to a trust; the trustee sets the ...
At week 12, 60% of patients without prior advanced therapy failure had an endoscopic response, versus 15% on placebo; ...
PRAME-high melanoma: 12.5-month median response duration; 91% alive at one year. First data on IMA402 with IMA401 in lung cancer are expected in 2027.
SUNS declared a prorated $0.09-per-share fourth-quarter dividend, payable Nov. 5 to holders of record Nov. 2; the merger ...
The analysis included 295 people and found reductions in all four urinary markers, adding evidence FILSPARI may affect ...
The 56% response rate came from 25 patients with CEA-high tumors; BeOne intends to advance both lung programs toward ...
KRAS mutations affect about 40% of colorectal cancers, and G12D is the most common. Genmab will conduct the study; Incyte ...
The 10:30 a.m. Eastern call will cover results for the six months ended June 30, operations and Q&A; the presentation deck ...
Newport Gold (NWPG) subsidiary NFI Empire announced Rockford Fosgate’s return as official audio partner for its Project ...
MakerSpace used 3D scans to give other manufacturers precise measurements for custom parts; auction proceeds will benefit The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results